FDA Approves Furoscix ReadyFlow - Summary - MDSpire

FDA Approves Furoscix ReadyFlow

Clinical data demonstrated achievement of the primary pharmacokinetic endpoint, with urine output and sodium and potassium excretion comparable with those observed with intravenous furosemide, according to MannKind.

  • By

  • Kathryn Wighton

  • July 24, 2026

  • 3 min

Share

Original Source(s)

FDA Approves Furoscix ReadyFlow

  • by Kathryn Wighton

  • July 24, 2026

Related Content

Long COVID May Raise Cardiovascular Risk

Population-based cohort shows higher rates of cardiac arrhythmias and coronary artery disease following nonhospitalized infections, with sex-specific differences.

IPS Could Minimize GI Effects in Treating Iron Deficiency

Review summarizes pharmacokinetic and clinical data on iron protein succinylate across patients with iron deficiency and iron deficiency anemia.

AHA: Coffee Need Not Be Avoided in AF

Moderate coffee consumption generally appeared safe for most adults, but randomized evidence suggested divergent effects on atrial fibrillation and premature ventricular contractions.